Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00487474
First received: June 15, 2007
Last updated: March 12, 2009
Last verified: March 2009
  Purpose
  • Measure the mid-facial volumetric correction from SCULPTRA treatment, using three-dimensional digital surface imaging
  • Determine the mean change from baseline in facial contour deficiency as measured by the Dermik Nasolabial Photo-numeric Scale
  • Correlate volumetric correction with clinical improvement as measured by the Dermik Nasolabial Photo-numeric Scale
  • Correlate the mean volumetric change in mid-facial treatment area with the amount of product used
  • Evaluate subject and investigator global assessment of improvement and subject treatment satisfaction at the end of treatment
  • Obtain photographs pre- and post-treatment for the purpose of providing a subject visual aid during the course of treatment
  • Collect safety data

Condition Intervention Phase
Mid Facial Contour Deficiencies
Device: DL6049 (injectable poly-L-lactic acid)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of Sculptra (Poly-L-Lactic Acid) Measured by Three Dimensional Digital Surface Imaging

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Measure the mid-facial volumetric correction from SCULPTRA treatment, using three-dimensional digital surface imaging. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the mean change from baseline in Nasolabial volume as measured by 3-D digital surface imaging [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Correlate volumetric correction with clinical improvement as measured by the Dermik Nasolabial Photo-numeric Scale. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Correlate the mean volumetric change in mid-facial treatment area with the amount of product used. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Determine mean change from baseline in the contour deficiency score as determined by the investigator. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Investigator Global Assessment of Improvement - Excellent Improvement [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Investigator Global Assessment of Improvement - Much Improved [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Investigator Global Assessment of Improvement - Improved [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Investigator Global Assessment of Improvement - No Change [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Investigator Global Assessment of Improvement - Worse [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Subject Global Assessment of Improvement - Excellent Improvement [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Subject Global Assessment of Improvement - Much Improved [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Subject Global Assessment of Improvement - Improved [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Subject Global Assessment of Improvement - No Change [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
  • Subject Global Assessment of Improvement - Worse [ Time Frame: 6 Months ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: June 2007
Study Completion Date: February 2008
Arms Assigned Interventions
Experimental: Sculptra Device: DL6049 (injectable poly-L-lactic acid)
Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
Other Name: Sculptra

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must sign a statement of informed consent.
  • Subjects must be 18-75 years of age, of any race or gender.
  • Female patients of childbearing potential must have a negative urine pregnancy test prior to the first treatment with the product and must use an acceptable form of birth control throughout the study (e.g., oral/systemic contraceptives, an intrauterine device (IUD) or Norplant starting at least 28 days prior to study entry and throughout the study).
  • Subjects must display signs of facial contour deficiencies in the area of the nasolabial folds [nasolabial fold scores greater than or equal to 2 (bilaterally) on the Dermik Nasolabial Photo-numeric Scale.
  • Subjects must be a suitable candidate for SCULPTRA treatment.
  • Subjects must be able to understand the requirements of the study and be willing to comply with the study requirements

Exclusion Criteria:

  • Subjects with an allergy to any of the constituents of the product.
  • Subjects with a known history of keloids or bleeding disorders.
  • Subjects of childbearing potential who are pregnant, or plan to become pregnant within the study timeframe, or who are nursing.
  • Subjects with significant facial hair (e.g. mustaches, beards, etc.)
  • Subjects with an active inflammatory process or infection in the area to be treated (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, or any other active skin disease in the treatment area).
  • Subjects who plan to undergo major facial surgery [e.g., rhinoplasty (with or without implant), facelift, congenital defect repair, etc.] during the course of the study.
  • Subjects who have used or plan to use exclusionary medications/treatments.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00487474

Locations
United Kingdom
London, United Kingdom
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Phyllis Diener, MT, ASCP Sanofi
  More Information

No publications provided

Responsible Party: Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00487474     History of Changes
Other Study ID Numbers: DL6049-0502
Study First Received: June 15, 2007
Last Updated: March 12, 2009
Health Authority: United Kingdom: Research Ethics Committee

ClinicalTrials.gov processed this record on November 25, 2014